Reading NRXP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NRXP free→Reading NRXP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NRXP free→QuarterlyIQ Insights · NRXP
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(25.0) + peer(0.2*10.7) + term(0.0) → 10.89% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
above. Disclaimer . The information contained in Items 2.02 and 7.01 of this Current Report on Form 8-K, and Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ” ), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
above. Also on May 15, 2025, the Company issued a press release announcing the signing of a non-binding term sheet with Hope Therapeutics, Inc. and an investor, for debt financing to Hope of up to $7.8 million (the “ Term Sheet ”), subject to the execution of definitive documentation and other customary closing conditions. A copy of the press release announcing the entrance into the Term Sheet is furnished hereto as Exhibit 99.2 and is incorporated herein by reference. Disclaimer . The inform…
Results of Operations and Financial Condition On March 17, 2025, NRx Pharmaceuticals, Inc. (the “ Company ”) hosted an earnings call and issued a press release announcing its financial results for the fourth quarter and fiscal year ending December 31, 2024, and provided a business update. A copy of the press release and a transcript of the earnings call are furnished hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.